BioSpace News Archive

The SenSight™ Directional Lead System Was Designed to Enable Precision, Personalization and Enhanced Patient Comfort

Company Demonstrates Existing Platform Can Synergize with Multiple Antigen Specific Tumor Immunotherapies

Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced the presentation of clinical data from its phase 1 dose-escalation study of LNS8801

Symptom most commonly observed in women and younger respondents, less commonly in those of East Asian and African American ancestry

Probo Medical (“Probo”), a leading global provider of medical imaging equipment, parts, repair and service, announced today the acquisition of Tenvision, LLC (“Tenvision”). Terms of the transaction were not disclosed.

Swift Biosciences , pioneers in the development of library preparation and targeted sequencing solutions for next generation sequencing (NGS) in research applications, has announced the release of Swift 2S™ Turbo v2 DNA Library Kits for whole genome and whole exome studies.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, commends Kate Julian and The Atlantic for highlighting the major crisis facing our society in her article America Has a Drinking Problem .

Herzing University, an accredited, private nonprofit institution with locations in seven states and a nationally recognized online division, announced it is starting a Licensed Practical Nurse program on its Madison, Wisconsin, campus.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that the first patients have been enrolled into a Phase 2 clinical study evaluating JNJ-40411813 in patients with epilepsy.

Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced its decision not to continue the collaboration and license agreement with argenx for cusatuzumab, an investigational therapeutic antibody that targets CD70.